Carroll Financial Associates’s Travere Therapeutics TVTX Stock Holding History

Carroll Financial Associates’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$62K	Hold	2,000	–	–	﹤0.01%	661
2021 Q3	$48K	Hold	2,000	–	–	﹤0.01%	753
2021 Q2	$29K	Hold	2,000	–	–	﹤0.01%	974
2021 Q1	$49K	Hold	2,000	–	–	﹤0.01%	777
2020 Q4	$54K	Buy	2,000 +1,000	+100%	+$23.3K	﹤0.01%	681
2020 Q3	$18K	Hold	1,000	–	–	﹤0.01%	895
2020 Q2	$20K	Hold	1,000	–	–	﹤0.01%	860
2020 Q1	$14K	Hold	1,000	–	–	﹤0.01%	865
2019 Q4	$14K	Hold	1,000	–	–	﹤0.01%	971
2019 Q3	$11K	Hold	1,000	–	–	﹤0.01%	979
2019 Q2	$20K	Hold	1,000	–	–	﹤0.01%	833
2019 Q1	$22K	Hold	1,000	–	–	﹤0.01%	732
2018 Q4	$23K	Hold	1,000	–	–	﹤0.01%	639
2018 Q3	$28K	Hold	1,000	–	–	﹤0.01%	622
2018 Q2	$27K	Hold	1,000	–	–	﹤0.01%	612
2018 Q1	$22K	Hold	1,000	–	–	﹤0.01%	651
2017 Q4	$21K	Hold	1,000	–	–	﹤0.01%	649
2017 Q3	$24K	Hold	1,000	–	–	﹤0.01%	618
2017 Q2	$19K	Hold	1,000	–	–	﹤0.01%	678
2017 Q1	$18K	Buy	+1,000	New	+$19.6K	﹤0.01%	696
2015 Q3	–	Sell	-1,000	Closed	-$33K	–	1171
2015 Q2	$33K	Hold	1,000	–	–	0.01%	446
2015 Q1	$24K	Buy	+1,000	New	+$15.2K	0.01%	392

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Carroll Financial Associates's TVTX Position: Q4 2021 in Review

Carroll Financial Associates held its Travere Therapeutics (TVTX) position steady in Q4 2021 at 2,000 shares worth $62K. The position accounts for ﹤0.01% of the portfolio, ranked #661.

Carroll Financial Associates first reported a position in TVTX in Q1 2015 and has held it in 22 quarters since. 169 funds tracked by Wall St. Rank hold TVTX as of Q4 2021.

Carroll Financial Associates held 2,000 shares of Travere Therapeutics worth $62K as of Q4 2021.
Carroll Financial Associates left its Travere Therapeutics share count unchanged in Q4 2021.
Travere Therapeutics made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #661 holding.
Carroll Financial Associates first reported a position in Travere Therapeutics in Q1 2015 and has held it in 22 quarters since.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.